Hetland O, Johnsen B, Janson T L, Prydz H
Scand J Clin Lab Invest. 1983 Feb;43(1):35-40.
Previous experiments (Gollub et al. [10]. Giercksky et al.) have shown that phospholipase C (PLC) has a protective effect on rats and rabbits receiving thromboplastin infusions. As a step towards the possible use of PLC in humans, we have investigated further the use of PLC in rabbits. Infusions of human or rabbit thromboplastin caused a rapid fall in factors V and VIII. LD50 for our standard human thromboplastin preparation was estimated to be 1.5--1.8 ml/kg. Highly purified PLC was given as an intravenous bolus immediately before thromboplastin. No improvement of survival and only a slight difference in factors V and VIII were observed, in contrast to earlier observations in the rat. This may in part be due to differences in the susceptibility to PLC of the thromboplastins used. PLC was also more toxic in rabbits than in rats.
先前的实验（戈卢布等人[10]。吉尔克斯基等人）表明，磷脂酶C（PLC）对接受凝血活酶输注的大鼠和兔子具有保护作用。作为朝着可能在人类中使用PLC迈出的一步，我们进一步研究了PLC在兔子中的应用。输注人或兔凝血活酶会导致因子V和VIII迅速下降。我们标准人凝血活酶制剂的半数致死量估计为1.5--1.8毫升/千克。在凝血活酶给药前立即静脉推注高纯度PLC。与早期在大鼠中的观察结果相比，未观察到生存率的改善，且因子V和VIII仅有轻微差异。这可能部分归因于所用凝血活酶对PLC敏感性的差异。PLC对兔子的毒性也比大鼠更大。
